Effect of Huachansu Capsules Combined with FOLFOX Regimen in the Treatment of Colorectal Cancer Patients
Objective:To investigate the effect of Huachansu Capsules combined with FOLFOX regimen in the treatment of colorectal cancer(CRC)patients.Method:The clinical data of 70 patients with CRC who admitted to Zhaoqing First People's Hospital from January 2022 to February 2023 were selected for study,according to whether Huachansu Capsules was used,they were divided into the observation group(35 cases)and the control group(35 cases).The control group was treated with FOLFOX regimen,while the observation group was treated with Huachansu Capsules on the basis of the control group.The short-term efficacy,serum tumor markers,inflammatory factors,Karnofsky functional status scale(KPS)scores before and after treatment,and the occurrence of toxic and side effects during treatment were compared between two groups.Result:The total effective rate in the near future of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).Before treatment,there were no statistically significant differences in the carbohydrate antigen 242(CA242),carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),interleukin-1β(IL-1β),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)and KPS scores between two groups(P>0.05);after treatment,the levels of CA242,CA125,CEA,IL-1β,IL-6,TNF-α of two groups decreased compared with those before treatment,and those in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05);after treatment,the KPS scores of two groups increased compared with those before treatment,and that in the observation group was higher than that in the control group,the differences were statistically significant(P<0.05).The incidence of gastrointestinal reactions and leukopenia during treatment in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05);there were no statistically significant differences in the incidence of renal dysfunction and abnormal liver function between two groups(P>0.05).Conclusion:Huachansu Capsules combined with FOLFOX regimen in the treatment of CRC patients can effectively improve clinical efficacy,reduce serum tumor markers and inflammation levels,improve patient functional status,and reduce side effects.
国家科技期刊平台
NSTL
万方数据
维普
